214 related articles for article (PubMed ID: 33745027)
1. Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonists.
Lang-Schwarz C; Melcher B; Dregelies T; Norouzzadeh Z; Rund-Küffner S; Lang-Schwarz K; Vieth M; Sterlacci W
Int J Colorectal Dis; 2021 Aug; 36(8):1765-1779. PubMed ID: 33745027
[TBL] [Abstract][Full Text] [Related]
2. Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists.
Lang-Schwarz C; Melcher B; Hartmann A; Bertz S; Dregelies T; Lang-Schwarz K; Vieth M; Sterlacci W
Int J Colorectal Dis; 2021 Nov; 36(11):2497-2510. PubMed ID: 34170390
[TBL] [Abstract][Full Text] [Related]
3. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
Lee H; Sha D; Foster NR; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
Ann Oncol; 2020 Apr; 31(4):487-494. PubMed ID: 32165096
[TBL] [Abstract][Full Text] [Related]
4. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
Saberzadeh-Ardestani B; Foster NR; Lee HE; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
Ann Oncol; 2022 Nov; 33(11):1159-1167. PubMed ID: 35963480
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy.
Morris M; Platell C; Iacopetta B
Clin Cancer Res; 2008 Mar; 14(5):1413-7. PubMed ID: 18316563
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy.
Cha YJ; Park EJ; Baik SH; Lee KY; Kang J
Sci Rep; 2019 Aug; 9(1):11617. PubMed ID: 31406179
[TBL] [Abstract][Full Text] [Related]
7. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups.
Lang-Schwarz C; Melcher B; Haumaier F; Lang-Schwarz K; Rupprecht T; Vieth M; Sterlacci W
Hum Pathol; 2018 Sep; 79():160-167. PubMed ID: 29787819
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer.
Efil SC; Guner G; Guven DC; Celikten B; Celebiyev E; Taban H; Akyol A; Isik A; Kilickap S; Yalcin S; Dizdar O
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102171. PubMed ID: 37352926
[TBL] [Abstract][Full Text] [Related]
9. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
10. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
11. Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsuda C; Nakamoto Y; Kotake M; Kurachi K; Egawa T; Yasumasa K; Murata K; Ikawa O; Shinji S; Murotani K; Matsui S; Teramukai S; Tomita N; Sugihara K;
J Clin Oncol; 2019 Aug; 37(22):1886-1894. PubMed ID: 31180819
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study.
Francini E; Ou FS; Lazzi S; Petrioli R; Multari AG; Pesola G; Messuti L; Colombo E; Livellara V; Bazzurri S; Cherri S; Miano ST; Wolfe EG; Alberts SR; Hubbard JM; Yoon HH; Francini G
Transl Oncol; 2021 Feb; 14(2):100973. PubMed ID: 33338878
[TBL] [Abstract][Full Text] [Related]
13. Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer.
Sinicrope FA; Shi Q; Smyrk TC; Goldberg RM; Cohen SJ; Gill S; Kahlenberg MS; Nair S; Shield AF; Jahagirdar BN; Jacobson SB; Foster NR; Pollak MN; Alberts SR
JNCI Cancer Spectr; 2021 Oct; 5(5):. PubMed ID: 34485815
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
16. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
[TBL] [Abstract][Full Text] [Related]
17. Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases.
Fuchs TL; Pearson A; Pickett J; Diakos C; Dewar R; Chan D; Guminski A; Menzies A; Baron-Hay S; Sheen A; Sioson L; Chou A; Gill AJ
Pathology; 2020 Aug; 52(5):515-521. PubMed ID: 32553444
[TBL] [Abstract][Full Text] [Related]
18. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
19. Computer-assisted stereology and automated image analysis for quantification of tumor infiltrating lymphocytes in colon cancer.
Eriksen AC; Andersen JB; Kristensson M; dePont Christensen R; Hansen TF; Kjær-Frifeldt S; Sørensen FB
Diagn Pathol; 2017 Aug; 12(1):65. PubMed ID: 28851404
[TBL] [Abstract][Full Text] [Related]
20. Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.
Ishiguro M; Mochizuki H; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Kanemitsu Y; Ueno H; Ishikawa T; Uetake H; Matsui S; Teramukai S; Sugihara K
BMC Cancer; 2012 Jul; 12():281. PubMed ID: 22769569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
